Cell & Tissue Culture Supplies Market

Cell & Tissue Culture Supplies Market Size (2023 to 2028)

The global cell and tissue culture supplies market is expected to be worth USD 51.87 billion by 2028 from USD 27.74 billion in 2023, growing at a CAGR of 13.33% from 2023 to 2028.

MARKET DRIVERS:

The global market for cell and tissue culture supplies is expected to experience significant growth in the coming years due to its increasing applications in biotechnology, cell therapy, and regenerative medicine. Cell culture involves extracting cells from plants or animals and cultivating them in a controlled laboratory environment for research purposes. To ensure proper cell growth, various supplies are required. These include growth media, which provide the necessary nutrients and conditions for cell development. Components such as pH levels, serum types and concentrations need to be optimized. Reagents such as antibiotics and amino acid supplements are commonly used in cell culture. Serum supplements, particularly fetal bovine serum, are frequently added to basal media. Contamination detection kits are essential to ensure the absence of contaminants. Cryoprotecting agents are used to prevent freezing damage to biological tissues during cryopreservation. Specialized equipment like culture systems, biosafety cabinets, incubators and cryo-storage equipment are utilized in cell and tissue culture. This technique finds applications in various fields such as vaccine production, drug screening and development, gene therapy, toxicity testing, cancer research and more.

The growing number of R&D activities drives the growth of the cell and tissue culture supplies market. The development of vaccines requires the synthesis of viral particles and cultivating techniques provide the necessary instruments for this. For instance, the demand for cytological services offered by contract research organizations is expected to increase because it is expensive and requires expertise to establish cell culture infrastructure. Additionally, research in regenerative therapy has experienced substantial growth recently, with significant investments in this field. Since cell culture techniques are crucial for such research, the market is predicted to grow significantly in the coming years. The widespread use of cell culture technology is also anticipated to be fueled by ongoing developments in regenerative medicine and the significant unmet medical needs in emerging economies. 

An increasing number of initiatives from the governments of various countries in favor of the healthcare industry further propels market growth. An example of this is seen in India, where the Union Health Ministry updated the pharmaceutical and clinical trials regulations in January 2022 to encompass products made from cells or stem cells as novel pharmaceuticals. This move provided a robust regulatory framework for the manufacturing of cell-derived products in the country, leading to positive prospects for industry growth.

The growing patient population suffering from chronic diseases contributes to the growth of the cell and tissue culture supplies market. More than 17.9 million people die each year because of cardiovascular diseases, which is one of the chronic diseases, according to the WHO. It is predicted that such a high number of deaths would raise interest in this area of study and expand the market for cell culture products. The WHO figures show that an increasing focus on cytological research has resulted from the rise in the prevalence of chronic illnesses, such as cancer and cardiovascular disorders, which has raised the demand for culture systems and media products.

MARKET RESTRAINTS:

The limitations in achieving high-density cell cultures are one of the major factors restraining market growth. While the adoption of advanced technologies like microcarriers is on the rise for high-density cell cultures, there are several drawbacks associated with their usage, making the cell culture process labor-intensive and costly. Some of these limitations include the necessity for agitation in a stirred-tank bioreactor to create a homogeneous cell culture system. Unfortunately, this agitation can damage cells, leading to the formation of cell debris and reduced cell yield, thereby increasing downstream processing expenses. Additionally, achieving higher culture density requires an increase in the number of microcarriers, which in turn leads to a higher occurrence of collisions (either between beads or between microcarrier-bound cells and mechanical impellers), resulting in cell death and diminished cell yield.

The high cost of cell and tissue culture supplies, stringent regulations and compliance requirements for cell and tissue culture products and limited availability of skilled professionals trained in cell and tissue culture techniques hinder the market growth. Challenges in scaling up cell and tissue culture processes to meet the demand for large-scale production, risk of contamination during cell and tissue culture processes, lack of standardization and variability in cell and tissue culture protocols, ethical considerations and controversies surrounding the use of animal-derived components in cell and tissue culture supplies and limited awareness and understanding of cell and tissue culture techniques among researchers and healthcare professionals further inhibits the market’s growth rate.

REPORT COVERAGE: 

This research report on the global cell and tissue culture supplies market has been segmented and sub-segmented based on the following categories.

Cell and Tissue Culture Supplies Market - By Consumables:

• Media
  • Minimum Essential Media (MEM)
  • RPMI 1640 Media
  • DMEM/F-12 Media
  • F-10 Serum Free Media
  • BME Media
  • Insect Media
  • Other Media
• Sera
  • Fetal Bovine Serum
  • Other Animal Serum
• Reagents
  • Albumin
  • Other

Based on consumables, the media segment is predicted to experience substantial growth during the forecast period and is primarily driven by the heightened demand for media products in research and development applications. The market penetration of media products has been enhanced by the availability of diverse alternatives that are serum- and animal-component-free, as well as customizable. The growing commercialization of specialized media specifically designed for stem cell applications further contributes to segmental growth.

On the other hand, the reagents segment is expected to exhibit the fastest CAGR rate throughout the forecast period owing to the increasing importance of albumin which plays a crucial role in supporting mammalian cultures by carrying serum-derived substances.

Cell and Tissue Culture Supplies Market - By Product:

• Culture Systems
• Incubators
• Centrifuges
• Cry Storage Equipment
• Biosafety Equipment
• Pipetting Instruments

Based on product type, the culture system segment is estimated to account for the major share of the worldwide market during the forecast period owing to the development of advanced and automated culture systems. For instance, CELLINK introduced its BIO CELLX bio-dispensing platform in March 2022, which automates 3D cell-based assays for drug discovery and cancer research, expanding growth opportunities for the segment.

The centrifuges segment is expected to witness substantial growth during the forecast period due to their increased efficiency and reliability in laboratory operations. Benchtop centrifuges offer reliability for everyday use, while bioprocessing centrifuges enable high-quality, rapid, and high-yield cell separation, driving their adoption.

Cell and Tissue Culture Supplies Market - By Application:

• Biopharmaceuticals
• Tissue Culture & Engineering
• Vaccine Production
• Drug Development
• Gene Therapy
• Toxicity Testing
• Cancer Research
• Others

Based on application, the biopharmaceutical segment is predicted to hold the leading share of the global cell and tissue culture supplies market during the forecast period owing to the utilization of mammalian cell lines, such as the Chinese hamster ovary, in biopharmaceutical manufacturing. The increasing demand for non-conventional drugs and the growth of personalized treatment options have further contributed to the expansion of biopharmaceutical applications in cell culture techniques.

The vaccine production segment is expected to witness a lucrative CAGR during the forecast period. Culturing techniques play a vital role in producing viral vaccines using cell lines like Madin-Darby Canine Kidney, pMK, Vero, HEK 293, and MRC 5. The accelerated vaccine approval processes and significant investments in vaccine manufacturing, driven by the COVID-19 pandemic, are likely to drive the growth of vaccine production applications in the industry.

Cell and Tissue Culture Supplies Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East & Africa

Based on region, North America is expected to lead the cell and tissue culture supplies market during the forecast period owing to factors such as extensive research and development activities, a well-established scientific infrastructure, and a significant demand for animal component-free media.

The European region accounted for a considerable share of the worldwide market in 2022 and is expected to account for a notable share of the global market during the forecast period.

The Asia Pacific region is expected to exhibit the fastest CAGR during the forecast period. This growth can be attributed to several factors including government initiatives supporting research on stem cell therapy, the increasing geriatric population, the growing prominence of regenerative medicine research, a rising number of researchers in Japan, favorable changes in FDI regulations in the pharmaceutical industry in India, and the growth of the pharmaceutical and biopharmaceutical sectors in South Korea. These factors collectively contribute to the growth of the cell culture industry in the Asia Pacific region.

KEY MARKET PLAYERS:

Some of the notable key market players include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Merck KGaA, Sartorius AG, VWR International, LLC, Eppendorf SE, PromoCell GmbH, Bio-Techne Corporation and BioSpherix, Ltd.

RECENT HAPPENINGS IN THE MARKET:

• In October 2022, Cytiva acquired Cevec Pharmaceuticals GmbH, which is expected to strengthen Cytiva’s leading position in biomanufacturing solutions.
• In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the US.
• In January 2022, BioIVT LLC, a U.S.-based biotechnology company, launched good manufacturing practices grade human AB serum for the development and manufacturing of cell and gene therapies. Human AB serum has wide applications. It supports in vitro cell expansion by providing growth factors, vitamins, nutrients, trace elements, and transport factors found in an in vivo environment. It helps primary human cells to grow at a faster rate by providing them with biologically relevant conditions. This is important for autologous therapies which require a person’s own cells or tissues. This serum is helpful for the rapid development of cell cultures.